Figure 8.
OS for 4 randomized groups excluding BMT patients: DAT/no CsA (n = 127) 51.2% ± 4.5%; DAT/CsA (n = 118) 50.2% ± 4.9%; for HDAT/no CsA (n = 122) 49.9% ± 4.6%; and for HDAT/CsA (n = 115) 51.6% ± 4.8%.
OS for 4 randomized groups excluding BMT patients: DAT/no CsA (n = 127) 51.2% ± 4.5%; DAT/CsA (n = 118) 50.2% ± 4.9%; for HDAT/no CsA (n = 122) 49.9% ± 4.6%; and for HDAT/CsA (n = 115) 51.6% ± 4.8%.
